Cipher Pharmaceuticals（CPH）株式概要
サイファー・ファーマシューティカルズ・インクはカナダで特殊医薬品会社として営業している。 詳細
報酬
リスク分析
リスクチェックの結果、CPH 、リスクは検出されなかった。
CPH Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Cipher Pharmaceuticals Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | CA$16.92 |
| 52週高値 | CA$20.56 |
| 52週安値 | CA$11.87 |
| ベータ | 0.49 |
| 1ヶ月の変化 | -8.49% |
| 3ヶ月変化 | 16.13% |
| 1年変化 | 39.83% |
| 3年間の変化 | 364.84% |
| 5年間の変化 | 1,135.04% |
| IPOからの変化 | 357.30% |
最新ニュース
分析記事 • May 14
Investors Shouldn't Be Too Comfortable With Cipher Pharmaceuticals' (TSE:CPH) Earnings
Cipher Pharmaceuticals Inc. ( TSE:CPH ) announced strong profits, but the stock was stagnant. Our analysis suggests...
ナラティブの更新 • May 08
CPH: Higher Cash Returns And Buybacks Will Support Future Upside
Analysts have lifted their price target on Cipher Pharmaceuticals to CA$21 from CA$20, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E. These changes support a slightly higher fair value estimate.Recent updates
分析記事 • May 14
Investors Shouldn't Be Too Comfortable With Cipher Pharmaceuticals' (TSE:CPH) Earnings
Cipher Pharmaceuticals Inc. ( TSE:CPH ) announced strong profits, but the stock was stagnant. Our analysis suggests...ナラティブの更新 • May 08
CPH: Higher Cash Returns And Buybacks Will Support Future Upside
Analysts have lifted their price target on Cipher Pharmaceuticals to CA$21 from CA$20, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E. These changes support a slightly higher fair value estimate.ナラティブの更新 • Apr 23
CPH: Higher Cash Flow Plans And Buybacks Will Support Future Upside
Analysts have nudged their fair value estimate for Cipher Pharmaceuticals to CA$21 from CA$20, tying the CA$1 price target change to updated assumptions around revenue growth, profit margins and a slightly higher discount rate alongside a lower future P/E. Analyst Commentary Recent research points to a modestly higher fair value for Cipher Pharmaceuticals, with bullish analysts lifting their price target to CA$21 from CA$20.
ナラティブの更新 • Apr 09
CPH: Fair Outlook Will Weigh Natroba Expansion And Acquisition Execution
Analysts have nudged their price target on Cipher Pharmaceuticals up to CA$21 from CA$20, citing updated assumptions that keep fair value broadly steady while fine tuning expectations around growth, margins, and P/E levels. Analyst Commentary The latest price target move to CA$21 from CA$20 signals only a modest reset in expectations, rather than a major shift in conviction.ナラティブの更新 • Mar 26
CPH: Balanced Outlook Will Weigh New Drug Review And Acquisition Execution
Analysts recently lifted their price target on Cipher Pharmaceuticals to CA$21 from CA$20, reflecting updated assumptions that combine a higher revenue growth outlook with slightly lower profit margin and future P/E expectations. Analyst Commentary The latest price target move to CA$21 suggests that covering analysts are refining their assumptions rather than making a sweeping change in their outlook.ナラティブの更新 • Mar 12
CPH: New Drug Review Will Support Future Upside Potential
Analysts are maintaining their CA$18.60 price target on Cipher Pharmaceuticals. This reflects only small adjustments to their revenue growth and future P/E assumptions, rather than a change in their overall view of the stock.ナラティブの更新 • Feb 26
CPH: New Drug Review And Strong Margins Will Support Further Upside
Analysts kept their CA$18.60 price target on Cipher Pharmaceuticals unchanged, citing only small tweaks to their revenue growth, profit margin and future P/E assumptions that did not materially shift their view of the stock’s value. What's in the News Health Canada accepted Cipher Pharmaceuticals' new drug submission for Natroba (Spinosad) for the treatment of head lice and scabies, moving the product into the formal review process (Key Developments).ナラティブの更新 • Feb 11
CPH: Higher Margins And New Submission Will Support Future Upside
Analysts have trimmed their price target on Cipher Pharmaceuticals to reflect a more muted revenue growth outlook of 4.30% and a slightly higher discount rate of 6.25%, while still acknowledging a stronger projected profit margin of 39.46% and a broadly similar future P/E of 17.63. What's in the News Health Canada accepted Cipher Pharmaceuticals' new drug submission for Natroba (Spinosad), targeting head lice and scabies in the Canadian market (Key Developments).ナラティブの更新 • Jan 26
CPH: Share Repurchases Will Drive Future Earnings Power And Upside Potential
Analysts have modestly adjusted their price target for Cipher Pharmaceuticals to reflect slightly updated assumptions around revenue growth of 10.48%, profit margin of 32.39%, and a future P/E of 17.81x. The overall fair value estimate remains at $18.60.ナラティブの更新 • Jan 11
CPH: Share Repurchases Will Support Stronger Future Earnings Profile
Analysts have trimmed their price target on Cipher Pharmaceuticals by aligning slightly lower revenue growth and profit margin assumptions with a modestly higher future P/E. This keeps fair value around $18.60 and reflects a more measured outlook on the company’s earnings profile.ナラティブの更新 • Dec 27
CPH: Share Repurchases And Rising Margins Will Support Stronger Future Earnings
Cipher Pharmaceuticals' analyst price target has been raised from 14.50 dollars to 18.60 dollars, as analysts cite slightly stronger expected revenue growth, modestly higher profit margins, and a richer future earnings multiple as justification for the upward revision. What's in the News Cipher Pharmaceuticals completed the latest tranche of its share repurchase program between July 1, 2025 and September 30, 2025, buying back 141,700 shares, or 0.56 percent of its float, for CAD 2.18 million (Key Developments) Under the buyback announced on May 1, 2025, the company has now repurchased a total of 371,978 shares, representing 1.46 percent of shares outstanding, for aggregate consideration of CAD 5.12 million (Key Developments) Valuation Changes The consensus analyst price target has risen significantly from 14.50 dollars to 18.60 dollars, reflecting a materially higher fair value assessment.ナラティブの更新 • Dec 12
CPH: Share Buybacks Will Support Earnings And Maintain A Balanced Outlook
Analysts have nudged their price target on Cipher Pharmaceuticals higher, from 14.00 dollars to 14.50 dollars, citing stronger expected revenue growth, improved profit margins, and a more attractive forward earnings multiple despite a slightly higher discount rate. What's in the News Cipher Pharmaceuticals repurchased 141,700 shares between July 1 and September 30, 2025, totaling CAD 2.18 million and representing 0.56% of outstanding shares (company buyback update).分析記事 • Nov 09
Cipher Pharmaceuticals Inc. (TSE:CPH) Analysts Are Pretty Bullish On The Stock After Recent Results
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shareholders are probably feeling a little disappointed, since its shares fell...分析記事 • Oct 10
These 4 Measures Indicate That Cipher Pharmaceuticals (TSE:CPH) Is Using Debt Extensively
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
ナラティブの更新 • Sep 05
Expansion Into Canada Will Shape Global Dermatology Success
Cipher Pharmaceuticals' future P/E has risen sharply, indicating increased valuation relative to earnings, while the net profit margin is stable, resulting in no change to the consensus analyst price target at CA$17.90. What's in the News Cipher Pharmaceuticals is actively seeking accretive acquisitions and in-licensing opportunities, with a strategic focus on complementary U.S.-based assets and companies.分析記事 • Aug 29
Cipher Pharmaceuticals Inc.'s (TSE:CPH) Shares Climb 27% But Its Business Is Yet to Catch Up
The Cipher Pharmaceuticals Inc. ( TSE:CPH ) share price has done very well over the last month, posting an excellent...分析記事 • May 16
We Think That There Are More Issues For Cipher Pharmaceuticals (TSE:CPH) Than Just Sluggish Earnings
Investors weren't pleased with the recent soft earnings report from Cipher Pharmaceuticals Inc. ( TSE:CPH ). Our...分析記事 • May 09
Cipher Pharmaceuticals Inc. (TSE:CPH) Stocks Shoot Up 29% But Its P/E Still Looks Reasonable
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shares have had a really impressive month, gaining 29% after a shaky period...分析記事 • Apr 28
Is Cipher Pharmaceuticals (TSE:CPH) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
新しいナラティブ • Feb 23
Acquisition Of Natroba And Pipeline Products Will Strengthen Future Market Presence
Strategic acquisitions and transitioning to an in-house sales team are aimed at reducing costs and boosting revenue and earnings for Cipher Pharmaceuticals.分析記事 • Dec 13
We Think Cipher Pharmaceuticals (TSE:CPH) Is Taking Some Risk With Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Nov 14
Cipher Pharmaceuticals' (TSE:CPH) Anemic Earnings Might Be Worse Than You Think
Cipher Pharmaceuticals Inc.'s ( TSE:CPH ) earnings announcement last week contained some soft numbers, disappointing...分析記事 • Nov 12
With A 29% Price Drop For Cipher Pharmaceuticals Inc. (TSE:CPH) You'll Still Get What You Pay For
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shareholders won't be pleased to see that the share price has had a very rough...分析記事 • Nov 09
Cipher Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shareholders are probably feeling a little disappointed, since its shares fell...分析記事 • Mar 23
There's No Escaping Cipher Pharmaceuticals Inc.'s (TSE:CPH) Muted Earnings Despite A 26% Share Price Rise
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shares have continued their recent momentum with a 26% gain in the last month...分析記事 • Mar 22
Weak Statutory Earnings May Not Tell The Whole Story For Cipher Pharmaceuticals (TSE:CPH)
The market rallied behind Cipher Pharmaceuticals Inc.'s ( TSE:CPH ) stock, leading do a rise in the share price after...株主還元
| CPH | CA Pharmaceuticals | CA 市場 | |
|---|---|---|---|
| 7D | -5.8% | -8.3% | -1.9% |
| 1Y | 39.8% | 35.2% | 31.1% |
業界別リターン: CPH過去 1 年間で35.2 % の収益を上げたCanadian Pharmaceuticals業界を上回りました。
リターン対市場: CPH過去 1 年間で31.1 % の収益を上げたCanadian市場を上回りました。
価格変動
| CPH volatility | |
|---|---|
| CPH Average Weekly Movement | 7.5% |
| Pharmaceuticals Industry Average Movement | 11.2% |
| Market Average Movement | 10.3% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 4.0% |
安定した株価: CPH 、 Canadian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: CPHの 週次ボラティリティ ( 7% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2000 | n/a | Craig Mull | www.cipherpharma.com |
サイファー・ファーマシューティカルズ・インクはカナダで特殊医薬品会社として事業を展開している。重度の結節性および／または炎症性ざ瘡、集簇性ざ瘡、難治性ざ瘡の治療を適応とする経口レチノイド薬Epuris（イソトレチノイン）、顔面、額、禿頭頭皮の軽度および／または中等度の厚さの過角化性光線性角化症（グレードI／II）の治療を適応とする外用液剤Actikerall、成人および小児患者のアタマジラミおよび疥癬の外用治療を適応とするNatrobaを提供している；Vaniqa：女性の顔のムダ毛の成長を遅らせる外用クリーム、Durela：成人の中等度から中等度の疼痛を管理するオピオイド鎮痛剤、Brinavess：成人の発症心房細動の洞調律への迅速な変換、Aggrastat：急性冠症候群患者に使用する可逆的GP IIb/IIIa阻害剤。同社のライセンス製品には、重度の結節性・炎症性ざ瘡、集簇性ざ瘡、難治性ざ瘡を適応症とする経口レチノイド剤Absoricaがある；リポフェンは、成人患者におけるLDL-C、総コレステロール、トリグリセリド、Apo Bの上昇を抑制し、HDL-Cを増加させ、トリグリセリドを減少させる食事療法の補助療法として適応がある。パイプライン製品としては、爪白癬の治療薬として第3相臨床試験中のテルビナフィン外用剤MOB-015、重度の尋常性乾癬と関節リウマチの治療薬として第3相臨床試験中のCF-101（ピクリデノソン）、前臨床試験段階のタトゥー除去クリームDTR-001などがある。同社は2000年に設立され、カナダのミシサガに本社を置いている。
Cipher Pharmaceuticals Inc. 基礎のまとめ
| CPH 基礎統計学 | |
|---|---|
| 時価総額 | CA$431.14m |
| 収益（TTM） | CA$42.42m |
| 売上高(TTM) | CA$70.00m |
10.1x
PER（株価収益率6.1x
P/SレシオCPH は割高か？
公正価値と評価分析を参照収益と収入
| CPH 損益計算書（TTM） | |
|---|---|
| 収益 | US$50.94m |
| 売上原価 | US$9.36m |
| 売上総利益 | US$41.58m |
| その他の費用 | US$10.71m |
| 収益 | US$30.87m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 1.22 |
| グロス・マージン | 81.63% |
| 純利益率 | 60.60% |
| 有利子負債／自己資本比率 | 0% |
CPH の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/20 02:07 |
| 終値 | 2026/05/20 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Cipher Pharmaceuticals Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8
| アナリスト | 機関 |
|---|---|
| David Novak | ATB Cormark Historical (Cormark Securities) |
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Prakash Gowd | CIBC Capital Markets |